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Abstract
Background
The present study was designed to evaluate the preconditioning effect of different doses of 
noradrenaline on ischemia-induced ventricular arrhythmias in open chest anesthetized rats.
Methods
The anaesthetized rats were subjected to 25 min of regional ischemia by left descending 
coronary artery (LAD) occlusion. In sham group, surgical procedures were done but ischemia 
was not applied. In control rats, saline was injected prior to ischemia. In noradrenaline groups, 
rats pretreated with three different doses of noradrenaline (respectively, 0.5, 1 and 2 μg/kg, IV). 
Results
In control rats, induction of ischemia shortened the QTc (corrected QT) interval (ms) and led to 
occurrence of ventricular arrhythmias. Administration of low-dose of noradrenaline prevented 
shortening of the QTc interval during ischemia but could not significantly attenuate severity and 
incidences of arrhythmias. Injection of mid-dose of noradrenaline stabilized the QTc during 
ischemia and reduced severity of arrhythmias. Pretreatment with high-dose of noradrenaline 
significantly prolonged the QTc interval and declined severity and incidence of arrhythmias. 
Conclusion
Noradrenaline dose-dependently attenuated ischemia-induced ventricular arrhythmias. 
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Introduction
The heart can protect itself against prolonged ischemic injury by prior exposure to one or more 
short-lasting periods of ischemia. This phenomenon, known as ischemic preconditioning (IPC) 
(1), presents one of the most effective manners for reducing the myocardial injury. 
Although preconditioning limits the extent of infarct size as a gold standard used in animal 
studies (2), its effect on arrhythmias is less clear with opposing results ranging from inhibition of 
arrhythmias (3) to its worsening (4).
One of the ways to achieve IPC-like cardioprotection is the stimulation of α1-adrenoceptors by 
catecholamines. In this regard, there are controversial reports from the effect of α1-adrenoceptor 
stimulation on ischemia-induced ventricular arrhythmias in the isolated rat heart. It has been 
shown that stimulation of this receptor worsens arrhythmias (5), whereas another study has 
indicated that transient stimulation of these receptors inhibits ischemia-induced ventricular 
arrhythmias (6). In addition, it has been shown that sympathetic activation triggers life-
threatening arrhythmias in rat heart (7). 
Many factors, which are absent in the isolated heart but present in vivo (e.g. hormonal and/or 
autonomic neural effect, circulatory system and loading of right ventricle) may also be important 
in the effect of catecholamines on ischemia- induced ventricular arrhythmias.
However, ethical considerations confine the experimental work on the human heart to assess the 
cardioprotection effect of preconditioning against ischemia injuries, the possibility that a 
myocardial protection might be inducible in the human heart has been led to experimental 
research on animals and it can only be attained when carefully planned clinical studies have been 
carried out in suitable patients with risk of coronary artery occlusion (8). In the clinical setting, 
there is some evidence to suggest that preconditioning may occur in patients with coronary 
artery disease (8-11). Patients suffering angina before a myocardial infarction (MI) have a better 
in-hospital prognosis and a reduced incidence of life-threatening ventricular arrhythmias (9). 
Previously, the latent protection conferred by ischemic preconditioning has been shown in the 
clinical setting that led to reduce the complications associated with the procedures such as 
precutaneous transluminal coronary angioplasty (PTCA) (10) and coronary artery bypass surgery 
(CABG) (11).
Therefore, the present study was designed to assess the preconditioning effect of different doses 
of   exogenous   administration   of   noradrenaline   (the   predominant   transmitter   of   cardiac 
sympathetic nerve) on ischemia-induced ventricular arrhythmias in open chest anesthetized rats.
Methods
Surgical Preparation 
Male wistar rats weightening 250–350 g (12-16 weeks old) were anesthetized by intraperitoneal 
administration of pentobarbital sodium (50 mg/kg body weight). The animal care was conducted 
in accordance with the institutional guidelines of Medical Sciences University of Tehran (I.R.) 
and the National Institutes of Health (NIH) guidelines for the care and use of laboratory animals. 
Surgical preparation to induce ischemia was performed by the following method (12,13):
The rats were tracheotomized in middle of the neck, intubated and ventilated with room air by a 
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Parvalux rodent ventilator (15 ml/kg stroke volume and 60–70 breaths/min). Body temperature 
was measured with a rectal thermometer and maintained at 37 ±1°C by the use of a lamp. The 
right carotid artery was cannulated and connected to a pressure transducer to measure mean 
arterial blood pressure (MBP). The tail vein was cannulated to allow administration of saline or 
drugs. A standard limb lead-II electrocardiogram (ECG) was monitored with subcutaneous 
stainless steel electrodes. ECG and MBP were recorded and heart rate was calculated using the 
Power Lab monitoring system (ML750 PowerLab/4sp). Rats were given heparin (200 IU/ kg, 
IV), and then the chest was opened by a left thoracotomy in the fifth intercostal space to expose 
the heart. After incision of the pericardium, a 6–0 silk suture was placed around the left anterior 
descending coronary artery (LAD), close to its origin. Both ends of a silk thread were passed 
through a polyethylene tube. Applying tension to the suture caused regional ischemia following 
coronary artery occlusion, and reperfusion was achieved by releasing the tension on the ligature. 
Ischemia was confirmed by ST elevation and increase in R-wave amplitude in ECG, or cardiac 
cyanosis. At the end of surgical procedure, any rat with a constant fall in MBP to less than 80 
mm Hg or ventricular fibrillation lasting for more than 5 min was discarded from the study. The 
end points used in this study were the severity and incidences of ventricular arrhythmias.
Assessment of ventricular arrhythmias
Ischemia-induced ventricular arrhythmias were determined in accordance with the Lambeth 
Conventions (14). Ventricular ectopic beats (VEBs) were defined as identifiable premature QRS 
complexes. Ventricular tachycardia (VT) was defined as the occurrence of four or more 
consecutive VEBs at a rate faster than the resting sinus rate. Ventricular fibrillation (VF) was 
defined as unidentifiable and low voltage QRS complexes. In the case of other multipart forms 
of VEBs such as bigeminy, couplet (two consecutive VEBs) and triplet (three consecutive 
VEBs), they were counted at separate episodes (Figure 1). Ventricular fibrillation may be 
sustained or may revert spontaneously to a normal sinus rhythm. VF lasting for more than 5 min 
was considered as irreversible.
A scoring system was used to calculate the severity of arrhythmias (15) where hearts with 0–50 
VEBs were given score 0; 50–500 VEBs a score of 1; more than 500 VEBs, or one episode of 
spontaneously reversible VT or VF a score of 2; 2–30 episodes of spontaneously reversible VT 
and/or VF a score of 3; more than 30 episodes of spontaneously reversible VT and/or VF a score 
of 4 and irreversible VF was given a score of 5. 
Evaluation of QT interval
The ECG tracings were analyzed visually and the following ECG parameters were examined: 
1) RR interval (the interval between the apex of two consecutive adjacent R waves), 
2) QT interval (the interval between beginning of Q wave and T wave apex), and 
3) Corrected QT interval (QTc), defined as the QT interval corrected for the heart rate by means 
of Bazett's equation: QTc = QT (ms)/[RR (s)]1/2(16).
Materials
Pentobarbital sodium and noradrenaline were obtained from Sigma Chemical Co. These 
chemical agents were dissolved in saline immediately before use.
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Experimental protocols 
All   animals   underwent   a   25   min   of   coronary   artery   occlusion.   Drugs   were   injected 
intravenously. After a stabilization period following the surgical preparation, rats were divided 
into five experimental groups.
Group-1: Sham-operated (n=9). Rats underwent surgical procedures without coronary artery 
ligation. 
Group- 2: Control (n=9). Saline was given 10 min before coronary artery occlusion. 
Group-3: NA-0.5 (n=6). Noradrenaline (0.5 µg/kg, i.v.) was administrated 10 min before 
coronary artery occlusion 
Group-4: NA-1 (n=6). Noradrenaline (1 µg/kg, i.v.) was administrated 10 min prior to 25-min 
ligation. 
Group-5: NA-2 (n=9). Noradrenaline (2 µg/kg, i.v.) was administrated 10 min before coronary 
artery occlusion. 
It   is   mentionable   that   different   doses   of   NA   were   chosen   by   preliminary   study.
Figure 1. Electrocardiogram recording. A: during baseline. B: during coronary artery occlusion. C: ventricular 
ectopic beat (VEB). D: bigeminy. E:couplet. F: ventricular tachycardia (VT). G: ventricular fibrillation (VF). 
Statistical analysis
Data are expressed as means±SD or the percentage of incidence. The parametric data were tested 
using the method Kolmogorov-Smirnov (KS). Statistical comparison of means between groups 
was performed by one-way ANOVA and a subsequent tukey test.
Within each group, differences between means in hemodynamic parameters were compared by 
one-way repeated measures ANOVA and a subsequent Bonferroni test. Differences between 
means in the QTc intervals were compared by paired t test. The incidences of VT or VF were 
compared using the Fisher exact test and the arrhythmia scores were analyzed with Kruskal-
Wallis test. Significant differences were determined as P<0.05.
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Table 1. Hemodynamic parameter
HR: Heart Rate (beats/min), MBP: Mean Arterial Blood Pressure (mmHg), NA: Noradrenaline. Data are presented 
as mean ± SD. * p<0.05 and ** p<0.01 compared with baseline within group and # p<0.05 compared with 
preocclusion within group. ∆1 changes: differences between preocclusion and baseline periods. ∆2 changes: 
differences between ligation and baseline periods.
Results
Hemodynamic
MBP and HR were continuously recorded during the experiments and calculated during the 15-
min baseline, preocclusion, and 25-min ischemia periods. No significant differences were found 
in HR and MBP between groups during baseline. Injection of different doses of noradrenaline 
caused a rapid and transient increase in MBP and HR, but they had returned to the baseline 
levels prior to LAD ligation. (Administration of low-dose of noradrenaline resulted in a non-
significant increase MBP, and injection of either the mid-dose or the high-dose of noradrenaline 
caused non- significant fall in MBP in preocclusion period when compared with baseline). The 
hemodynamic changes are outlined in Table 1.
Ventricular arrhythmias during ischemia
In this model of regional ischemia, severe ventricular arrhythmias peaked after 7 to 15 minutes 
of coronary artery occlusion.
Incidences of VT or VF 
Surgical procedures were not led to occurrence of VT or VF in sham-operated rats and VEBs 
only displayed in many hearts. In the control non-preconditioned hearts, VT was observed in 
100% of rats and 55.5 % of the hearts displayed VF. Pretreatment with 0.5 or 1 µg/kg of 
noradrenaline had no effect on incidences of VF and VT during 25-min ischemia. On the other 
hand, administration of high-dose of noradrenaline prior to ischemia, attenuated VT to 44.5% 
and totally abolished VF compared to the saline control rats (Figure 2A).
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Table 2. Electrocardiogram Parameters
NA: Noradrenaline, QTc: corrected QT interval (ms). Data are presented as mean ±SD. * p<0.05 compared to 
baseline within groups. ∆1 changes: differences between preocclusion and baseline periods. ∆2 changes: differences 
between the ligation and baseline periods.
A                                                                        B
Figure 2. A: The incidence of VF and VT B: Distribution of the arrhythmia score during 25 min ischemia in 
SHAM, Control (CON) and different doses of noradrenaline (NA-0.5, NA-1 and NA-2) groups. *** p<0.001 and ** 
p<0.01 vs. sham group. # # p<0.01 and # p<0.05 vs. control group.
Severity of arrhythmias
Coronary artery occlusion increased the severity of arrhythmias in the saline-treated control 
compared to sham-operated rats. Compared to control, severity of ventricular arrhythmias 
significantly declined by injection of noradrenaline (1 or 2 µg/kg) prior to ischemia (2.2±1.5 and 
1.7±1.2 vs. 3.9±0.9 in control rats). Injection of 0.5 µg/kg of noradrenaline had no protective 
effect on severity of ischemia-induced arrhythmias (3.25±0.6) (Figure 2B).
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It was revealed that significantly, there was an inverted correlation between pretreatment with 
different doses of noradrenaline and severity of arrhythmias during 25-min ischemia (R= - 0.75, 
p<0.01) (Figure 2B).
Number of episodes of VEB/ min 
Compared to control, number of episodes of VEB/min significantly improved by injection of 
noradrenaline (1 or 2 µg/kg) prior to ischemia (4±1 and 2.5±1.2 vs. 9.5±4.5 in control rats). 
Injection of 0.5 µg/kg of noradrenaline had no protective effect on number of episodes of VEB/
min (7±1.6) (Figure 3).
Figure 3. Number of episodes of ventricular ectopic beats/min (VEBs/min).Different doses of noradrenaline (NA-
0.5, NA-1and NA-2). Data are presented as mean ± SD. *** p<0.001 vs. Sham. # p<0.05 and # # # p<0.001 vs. 
control group.
Corrected QT (QTc) interval 
The change in QTc interval (ms) was measured between the baseline and 25-min ischemia 
periods within groups (Table 2). In the saline control rats, the induction of 25-min ischemia 
significantly   reduced   the   QTc   interval   compared   to   the   baseline   period   (p<0.05).   By 
administration of 0.5 or 1 µg/kg of noradrenaline, the QTc interval during prolonged ischemia 
was not significantly changed compared to the baseline period. Injection of 2 µg/kg of 
noradrenaline significantly increased the QTc interval (p<0.05) during prolonged ischemia 
compared to the baseline period. 
Discussion
In this study, noradrenaline dose-dependently prolonged the QTc interval and reduced severity 
and incidences of ventricular arrhythmias.
The protection does not appear to be due to an increase in coronary artery flow because 
noradrenaline administration did not enhance MBP in 25-min ischemia period and similar to 
other groups, occlusion of LAD led to a fall in MBP.
The heart rate is another parameter that might play a part in arrhythmogenesis (17). In our study, 
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there was no difference in the heart rate during ischemia period among the groups, and then it 
seems that the heart rate had no effect on arrhythmogenesis. 
The QT interval is affected by heart rate and to assess the QT interval independently of heart 
rate, it is expressed as a corrected QT (QTc). It is generally believed that the QT interval is 
determined by the action potential duration (APD) of the ventricular myocytes (18). It is notable 
that ischemia-induced arrhythmias originate from the boundary zone between the normal region 
and  ischemic  area.  In the boundary zone, shortening  of APD during ischemia will be 
accompanied by a shortening of refractoriness, which would be proarrhythmic (19).
In our experiment, 25-min regional ischemia shortened the QTc interval and induced ventricular 
arrhythmias. Administration of different doses of noradrenaline prevented the shortening of QTc 
interval during ischemia and only injection of maximum dose of noradrenaline (2µg/kg) 
significantly prolonged the QTc interval and reduced severity and incidence of ventricular 
arrhythmias. Therefore, it seems that antiarrhythmic effect of noradrenaline is very similar to 
many related drugs such as amiodarone (20). This effect most probably mediates via QTc 
prolongation. 
It is proposed that administration of catecholamine prolongs the refractoriness and APD via the 
α1-adrenoreceptor activation (21). In an earlier study, we concluded the contribution of the α1-
adrenoreceptors to the protection of noradrenaline-induced preconditioning (22). Therefore, it 
seems   that noradrenaline  by prolonging  the QTc interval,  action   potential  duration  and 
subsequent refractoriness could improve the ischemia-induced ventricular arrhythmias. 
It is assumed that in ischemic myocardium, catecholamines are involved in worsening of 
arrhythmias by increasing automaticity and triggered activity (23), but it has been shown that 
there is no relationship between circulating catecholamines and occurrence of arrhythmias in 
clinical (24) and experimental studies (25). In our study, noradrenaline pretreatment could 
improve ischemia-induced ventricular arrhythmia in the anesthetized rat heart as we expected. 
Administration of catecholamine has been shown to inhibit Na+ accumulation and K+ loss 
during myocardial ischemia (26), which maybe the reason for ischemia-induced ventricular 
arrhythmias suppression by noradrenaline. 
In general, the accessible evidence supports the idea that preconditioning within clinical 
procedures   may   be   advantageous   to   patients.   However,   α1-antagonists   that   are   now 
recommended as one of the first-line drugs in the management of hypertension (27) could be 
potentially   deleterious   agents   that   may   either   abolish   or   prevent   the   development   of 
preconditioning. It has been shown that the use of prazosin (a selective α1-antagonist) increases 
the number of chest pain episodes and ST-segment deviations in ECG from the baseline in the 
patients with unstable angina. On the other hand, it is possible that ß-blocker-induced reduction 
in mortality and morbidity in patients with myocardial infarction (28) may also be mediated by 
induction   of   cardioprotection   by   allowing   endogenous   noradrenaline   to   activate   α1- 
adrenoceptors. 
Conclusion
Noradrenaline dose-dependently attenuated ischemia-induced arrhythmias in the rat heart in 
vivo.
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